DDInter817 DDInter1658
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Gilteritinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Gilteritinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deutetrabenazine
Gilteritinib {u} may lead to a major life threatening interaction when taken with {v} Dronedarone
Gilteritinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Gilteritinib may lead to a major life threatening interaction when taken with Dronedarone
Gilteritinib may lead to a major life threatening interaction when taken with Troleandomycin